

## **Indonesia Support for Injection Safety Devices**

## This Decision Letter sets out the Programme Terms of a Programme.

1.	Country: Indonesia
2.	Grant number: 17-IDN-32a-Y

- 3. Date of Decision Letter: 22 May 2017 (Replaces the previous Decision Letter dated 20 February 2017)
- 4. Date of the Partnership Framework Agreement: 30 December 2014
- 5. Programme title: Injection safety devices<sup>1</sup>
- 6. Programme duration<sup>2</sup>: 2017
- 7. Programme Budget (indicative): (subject to the terms of the partnership framework agreement)

	2017	Total <sup>3</sup>
Programme Budget (US\$)	163,500	163,500

8. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement)<sup>4</sup>

TOTAL injection safety devices to be purchased with Gavi funds in each year	2017
Number of AD syringes	3,234,400
Number of re-constitution syringes	
Number of safety boxes	35,600
Annual Amounts for injection safety devices for all Gavi vaccines (US\$)	163,500

<sup>&</sup>lt;sup>1</sup> This does not include vaccines.

<sup>&</sup>lt;sup>2</sup> This is the entire duration of the Programme.

<sup>&</sup>lt;sup>3</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>&</sup>lt;sup>4</sup> This is the amount that Gavi has approved.



## Injection safety devices to be purchased with Gavi funds in each year, by type of support

New Vaccine Support (NVS), HPV Quadrivalent, 1 dose(s) per vial, LIQUID,Demonstration	2017
New Vaccine Support (NVS), Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID,Routine	2017
Number of AD syringes	3,234,400
Number of safety boxes	35,600
Annual Amounts for injection safety devices for Vaccine (US\$)	163,500

- 9. Procurement agency: Not applicable
- 10. Self-procurement: Indonesia has elected to self-procure vaccines and injection safety devices in lieu of procuring through a Gavi agency. The applicable terms of the Partnership Framework Agreement and relevant Gavi guidelines and policies on self-procurement shall apply.
- 11. Co-financing obligations:

Co-financing requirements are listed in the relevant vaccine Decision Letter.

Signed by,

On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

dilart. Its brill

22 May 2017